Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate
- PMID: 1288512
Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate
Abstract
The efficacy and tolerance of a garlic preparation (Sapec, Kwai) was investigated in a randomized double-blind study vs. bezafibrate. This multi-centre study was conducted in 5 general medical practices and involved 98 patients with primary hyperlipoproteinaemia. The daily doses of the active substances were 900 mg of garlic powder (standardized as to 1.3% alliin) and 600 mg of bezafibrate, respectively. The pre-phase with placebo lasted 6 weeks, the treatment period covered 12 weeks. All patients were advised to observe a low-fat "step-1 diet" for the duration of the study. The 98 case report forms allowed the statistical evaluation of total cholesterol, HDL cholesterol and triglyceride levels for 94 patients, and of LDL cholesterol values for 92 patients. In the course of the treatment both study medications caused a statistically highly significant reduction in total cholesterol, in LDL cholesterol and triglycerides, and an increase in HDL cholesterol. However, there was no significant difference in the efficacies of both medication groups. Side effects were mentioned by 5 patients each in both treatment groups, none of which led to the withdrawal of the patients. Concerning the garlic preparation, there was no correlation between the perception of garlic odour and the influence on the cholesterol level.
Similar articles
-
Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.Atherosclerosis. 1987 Feb;63(2-3):203-9. doi: 10.1016/0021-9150(87)90122-5. Atherosclerosis. 1987. PMID: 3827981
-
Treatment of hyperlipidaemia with garlic-powder tablets. Evidence from the German Association of General Practitioners' multicentric placebo-controlled double-blind study.Arzneimittelforschung. 1990 Oct;40(10):1111-6. Arzneimittelforschung. 1990. PMID: 2291748 Clinical Trial.
-
[Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].Clin Ter. 1988 Mar 15;124(5):373-81. Clin Ter. 1988. PMID: 2974348 Italian. No abstract available.
-
[Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].Schweiz Med Wochenschr. 1985 Jun 29;115(26):907-11. Schweiz Med Wochenschr. 1985. PMID: 3927481 Clinical Trial. German.
-
Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.Atherosclerosis. 1992 Jan;92(1):31-40. doi: 10.1016/0021-9150(92)90007-4. Atherosclerosis. 1992. PMID: 1575820 Clinical Trial.
Cited by
-
Effect of garlic on blood pressure: a systematic review and meta-analysis.BMC Cardiovasc Disord. 2008 Jun 16;8:13. doi: 10.1186/1471-2261-8-13. BMC Cardiovasc Disord. 2008. PMID: 18554422 Free PMC article.
-
Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: A review and meta-analysis.Exp Ther Med. 2020 Feb;19(2):1472-1478. doi: 10.3892/etm.2019.8374. Epub 2019 Dec 27. Exp Ther Med. 2020. PMID: 32010325 Free PMC article.
-
Garlic as a lipid lowering agent--a meta-analysis.J R Coll Physicians Lond. 1994 Jan-Feb;28(1):39-45. J R Coll Physicians Lond. 1994. PMID: 8169881 Free PMC article.
-
Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients.Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD007653. doi: 10.1002/14651858.CD007653.pub2. Cochrane Database Syst Rev. 2012. PMID: 22895963 Free PMC article.
-
Use of lipid-lowering medicinal herbs during pregnancy: A systematic review on safety and dosage.ARYA Atheroscler. 2017 May;13(3):135-155. ARYA Atheroscler. 2017. PMID: 29147122 Free PMC article. Review.